Physician profile
Brandon Abbott
NPI 1356875702
$6,928.66
in general payments reported to CMS, 2019-2025
44 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $299 · 2021: $1,252 · 2022: $1,625 · 2023: $1,260 · 2024: $1,163 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,752.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,476.53 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $953.75 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $691.82 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $670.40 | 2021-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $605.88 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $374.74 | 2020-2025 | |
| Dexcom, INC. | $238.72 | 2022-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $200.21 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $199.39 | 2020-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Vanda Pharmaceuticals INC. | $124.28 | 2022-2023 | Hetlioz |
| Teva Pharmaceuticals USA, INC. | $123.81 | 2021-2024 | Uzedy |
| Novartis Pharmaceuticals Corporation | $106.97 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.74 | 2022-2023 | |
| Abbott Laboratories | $87.41 | 2021-2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.99 | 2021-2023 | Jardiance |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.